Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03275857 · ClinicalTrials.gov registry record · Early Phase 1

Cisplatin in Castration Resistant Prostate Cancer

A Early Phase 1 study of Prostate Cancer, sponsored by University of Rochester.

Completed
Registry status
Early Phase 1
Development phase
12
Enrollment target
1
Study location

NCT03275857: Completed Early Phase 1 study of Prostate Cancer, sponsored by University of Rochester.

NCT03275857 is a Early Phase 1 study of Prostate Cancer that has completed, run by University of Rochester. The registered enrollment target is 12 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03275857, a Early Phase 1 study of Prostate Cancer, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Early Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.

Primary Outcome

Measures of response will be decline in Prostate Specific Antigen (PSA) and regression of metastases.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Cisplatin

Study Locations (1)

New York

  • Wilmot Cancer Institute - Rochester

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2018-09-21
Est. Completion 2023-07-31
Phase Early Phase 1
University of Rochester

636 total trials

What the finished NCT03275857 record still lists

NCT03275857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin is the first listed.

NCT03275857 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT03275857 about?

NCT03275857 is a clinical study titled "Cisplatin in Castration Resistant Prostate Cancer". It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.

What is the current status of trial NCT03275857?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2018-09-21. Estimated completion is 2023-07-31.

What conditions does trial NCT03275857 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03275857?

The interventions under investigation include: Cisplatin (DRUG).

Who is sponsoring clinical trial NCT03275857?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03275857 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03275857's enrollment target sits among peer trials

12 703rd of 735 higher than 23 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03275857, the US trial registry maintained by the National Library of Medicine. NCT03275857 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.